Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag ultomiris

Apellis set to take on Alexion as FDA clears PNH drug Empaveli

pharmaphorum

MAY 17, 2021

There had been speculation that the FDA might approve Empaveli (pegcetacoplan) only as a backup option for patients who don’t see a sufficient benefit with Alexion’s Soliris (eculizumab) or Ultomiris (ravulizumab), but the regulator opted for a broad indication that included first-line treatment for PNH. billion and $1.1

Drugs

Drugs FDA Approval Marketing Clinical Trials

With rivals threatening, Argenx scores key myasthenia gravis win

pharmaphorum

MARCH 23, 2022

Vyvgart (efgartigimod alfa) became the first drug in the FcRn class to be approved by the FDA last December, and despite a $225,000 annual price tag is predicted to make relatively modest sales in its IV version, which will compete with other IV gMG drugs like AstraZeneca/Alexion’s C5 inhibitor Soliris (eculizumab).

Antibody

Antibody Sales FDA Approval Trials

Apellis set to take on Alexion as FDA clears PNH drug Empaveli

With rivals threatening, Argenx scores key myasthenia gravis win

Stay Connected